Compounds for use in inducing myocardial perfusion recovery
A calcitonin gene-related peptide (CGRP) compound can be selected from N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]ethoxy}ethoxy)acetyl][Ser1]alpha-human CGRP peptide (α-CGRP-analogue), or derivatives thereof; or N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), or derivatives thereof. The CGRP compound can be used to induce myocardial perfusion recovery, in connection with AMI, by activating any CGRP family of receptors with a larger CGRP compound: CGRP potency ratio in the coronary artery than in the mesenteric artery.
1. A method for the treatment of acute myocardial infarction (AMI), the method comprising:
administering a calcitonin gene-related peptide (CGRP) compound,
wherein the CGRP compound is N-alpha-[2-(2-{2-[(S)]-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (β-CGRP-analogue), and a pharmaceutically acceptable salts and solvates thereof,
wherein the CGRP compound is administered at least once per day, and
wherein the CGRP is administered for one to thirty consecutive days immediately after incident.
2. The method for treatment according to claim 1 , wherein said CGRP compound is human.
3. The method for treatment according to claim 1 , wherein said CGRP compound is substituted.
4. The method for treatment according to claim 3 , wherein said CGRP compound comprises polyethylene glycole (PEG).
5. The method for treatment according to claim 3 , wherein said CGRP compound comprises a biomarker.
6. The method for treatment according to claim 1 , wherein said CGRP compound is delivered in combination with one or more compounds selected from the group consisting of a beta blocker, a renin-angiotensin-system (RAS) inhibitor, an angiotensin 1 (AT1) blocker, a recombinant tissue plasminogen activator (TPA), an antithrombolytic, a new oral anticoagulant (NOAC), and an opioid,
wherein the beta blocker is metoprolol or propranolol,
wherein the RAS inhibitor is ramipril, enalapril, or captopril,
wherein the AT1 blocker is losartan, valsartan, or candesartan,
wherein the recombinant TPA is alteplase,
wherein the antithrombolytic is aspirin, heparin, warfarin, or clopidogrel,
wherein the NOAC is dabigatran, rivaroxaban, oxygen, or nitroglycerin, and
wherein the opioid is morphine.
7. The method for treatment according to claim 1 , wherein said CGRP compound is delivered by subcutaneous, intraperitoneal, or intravenous administration.
8. The method for treatment according to claim 1 , wherein said CGRP compound is administered locally in connection with percutan coronar intervention (PCI).
9. The method for treatment according to claim 1 , wherein said CGRP compound is administered in connection with an incident of AMI.
10. The method for treatment according to claim 9 , wherein said CGRP compound is administered within one hour after the AMI incident.
11. The method for treatment according to claim 1 , wherein the CGRP compound is administered repeatedly.
12. The method for treatment according to claim 1 , wherein the CGRP compound is administered in an amount of between 0.01 to 1000 nanomole/kg body weight.
13. The method for treatment according to claim 5 , wherein the biomarker is a fluorescent marker.
14. The method of treatment according to claim 1 , wherein said CGRP compound induces myocardial perfusion recovery in connection with AMI.
15. The method of treatment according to claim 14 , wherein said CGRP compound induces myocardial perfusion recovery by activating any CGRP family of receptors with a larger CGRP:CGRP compound potency ratio in coronary artery than in mesenteric artery.